A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
3期
进行中（已停止招募）
NCT06220604
| 适应症 | Plaque Psoriasis |
|---|
| 分期 | 3期 |
|---|
| 申办方 | Janssen Research & Development, LLC |
|---|
| 状态 | 进行中（已停止招募） |
|---|
| 受试者人数 | 731 人 |
|---|
| 干预（药物） | JNJ-77242113, JNJ-77242113 Matching Placebo, Deucravacitinib, Deucravacitinib Matching Placebo |
|---|
| 开始日期 | 2024年3月9日 |
|---|
| 完成日期 | 2024年11月15日 |
|---|
| 结果公布日 | 2026年6月25日 |
|---|
摘要
The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16
Week 16 · Percentage of participants
| Arm 1: Placebo Followed by JNJ-77242113 200 mg | 8.6 Percentage of participants |
|---|
| Arm 2: JNJ-77242113 200 mg | 70.9 Percentage of participants |
|---|
| p-value | <0.001 |
|---|
| Treatment difference | 62.6 (95% CI 53.3–69.5) |
|---|
Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 16
Week 16 · Percentage of participants
| Arm 1: Placebo Followed by JNJ-77242113 200 mg | 1.2 Percentage of participants |
|---|
| Arm 2: JNJ-77242113 200 mg | 57.5 Percentage of participants |
|---|
| p-value | <0.001 |
|---|
| Treatment difference | 56.5 (95% CI 49.0–62.4) |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
同一适应症的其他试验
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。